Sorrento Presents Preliminary Results of STI-2020 Against COVID-19
Shots: Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future sales of therapies emerges during the collaboration Sarepta gets an exclusive option to license Codiak’s technology to develop and commercialize engineered exosome therapies for up […]Read More
